George Tonn
About
George Tonn is a scholar working on Molecular Biology, Oncology and Physiology.
According to data from OpenAlex, George Tonn has authored 31 papers receiving a total of 939 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 9 papers in Oncology and 6 papers in Physiology. Recurrent topics in George Tonn's work include Receptor Mechanisms and Signaling (6 papers), Chemokine receptors and signaling (5 papers) and Pregnancy and preeclampsia studies (4 papers). George Tonn is often cited by papers focused on Receptor Mechanisms and Signaling (6 papers), Chemokine receptors and signaling (5 papers) and Pregnancy and preeclampsia studies (4 papers). George Tonn collaborates with scholars based in United States, Canada and Netherlands. George Tonn's co-authors include Julio C. Medina, James E. Axelson, Heng‐Keang Lim, Amin A. Nomeir, Scott Grimm, Chuang Lu, Kan He, Tian J. Yang, Konstantine W. Skordos and Regina W. Wang and has published in prestigious journals such as PLoS ONE, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.
In The Last Decade
George Tonn
30 papers receiving 897 citations
Peers
George Tonn
Kenneth J. Ruterbories United States
Hiroshi Komura Japan
William R. Brian United States
Sharon L. Ripp United States
Rao N. V. S. Mamidi United States
Satoru Asahi Japan
Michael Schrag United States
Praveen M. Bahadduri United States
Jairam Palamanda United States
Paul Rowland United Kingdom
Citations per year, relative to George Tonn George Tonn (= 1×)
peers
Kenneth J. Ruterbories
Countries citing papers authored by George Tonn
Since
Specialization
Citations
This map shows the geographic impact of George Tonn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by George Tonn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites George Tonn more than expected).
Fields of papers citing papers by George Tonn
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by George Tonn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by George Tonn. The network helps show where George Tonn may publish in the future.
Co-authorship network of co-authors of George Tonn
This figure shows the co-authorship network connecting the top 25 collaborators of George Tonn. A scholar is included among the top collaborators of George Tonn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with George Tonn. George Tonn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Grievink, Hendrika W., Jules A. A. C. Heuberger, Fen Huang, et al.. (2019). DNL 104, a Centrally Penetrant RIPK 1 Inhibitor, Inhibits RIP 1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers. Clinical Pharmacology & Therapeutics. 107(2). 406–414.
2.
Ma, Zhihua, Daniel C.-H. Lin, Rajiv Sharma, et al.. (2015). Discovery of the imidazole-derived GPR40 agonist AM-3189. Bioorganic & Medicinal Chemistry Letters. 26(1). 15–20.
3.
Bergeron, Marcelle, C O Willits, Simeon Bowers, et al.. (2013). Pharmacological inhibition of Polo Like Kinase 2 (PLK2) does not cause chromosomal damage or result in the formation of micronuclei. Toxicology and Applied Pharmacology. 269(1). 1–7.
4.
Henne, Kirk R., Thuy Tran, Brooke M. VandenBrink, et al.. (2012). Sequential Metabolism of AMG 487, a Novel CXCR3 Antagonist, Results in Formation of Quinone Reactive Metabolites That Covalently Modify CYP3A4 Cys239 and Cause Time-Dependent Inhibition of the Enzyme. Drug Metabolism and Disposition. 40(7). 1429–1440.
5.
Chen, Xiaoqi, Jeff Mihalic, Darin J. Gustin, et al.. (2011). Discovery of potent and specific CXCR3 antagonists. Bioorganic & Medicinal Chemistry Letters. 22(1). 357–362.
6.
Lin, Daniel C.-H., Jane Zhang, Run Zhuang, et al.. (2011). AMG 837: A Novel GPR40/FFA1 Agonist that Enhances Insulin Secretion and Lowers Glucose Levels in Rodents. PLoS ONE. 6(11). e27270–e27270.
7.
Gullapalli, Rampurna Prasad, Elaine Merisko‐Liversidge, Erich Goldbach, et al.. (2011). A Formulation Strategy for Gamma Secretase Inhibitor ELND006, a BCS Class II Compound: Development of a Nanosuspension Formulation with Improved Oral Bioavailability and Reduced Food Effects in Dogs. Journal of Pharmaceutical Sciences. 101(4). 1462–1474.
8.
Wong, Simon, Peter W. Fan, Raju Subramanian, et al.. (2010). Bioactivation of a Novel 2-Methylindole-Containing Dual Chemoattractant Receptor-Homologous Molecule Expressed on T-Helper Type-2 Cells/d-Prostanoid Receptor Antagonist Leads to Mechanism-Based CYP3A Inactivation: Glutathione Adduct Characterization and Prediction of In Vivo Drug-Drug Interaction. Drug Metabolism and Disposition. 38(5). 841–850.
9.
Liu, Jiwen, Yingcai Wang, Ying Sun, et al.. (2009). Tetrahydroquinoline derivatives as CRTH2 antagonists. Bioorganic & Medicinal Chemistry Letters. 19(24). 6840–6844.
10.
Liu, Jiwen, Zice Fu, An‐Rong Li, et al.. (2009). Optimization of a series of quinazolinone-derived antagonists of CXCR3. Bioorganic & Medicinal Chemistry Letters. 19(17). 5114–5118.
11.
Grimm, Scott, Heidi J. Einolf, Kan He, et al.. (2009). The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America. Drug Metabolism and Disposition. 37(7). 1355–1370.
12.
Du, Xiaohui, Darin J. Gustin, Xiaoqi Chen, et al.. (2009). Imidazo-pyrazine derivatives as potent CXCR3 antagonists. Bioorganic & Medicinal Chemistry Letters. 19(17). 5200–5204.
13.
Tonn, George, Simon Wong, Sylvia Wong, et al.. (2008). An Inhibitory Metabolite Leads to Dose- and Time-Dependent Pharmacokinetics of (R)-N-{1-[3-(4-Ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d ]pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxy-phenyl)-acetamide (AMG 487) in Human Subjects After Multiple Dosing. Drug Metabolism and Disposition. 37(3). 502–513.
14.
Du, Xiaohui, Xiaoqi Chen, Jason Duquette, et al.. (2007). Design and optimization of imidazole derivatives as potent CXCR3 antagonists. Bioorganic & Medicinal Chemistry Letters. 18(2). 608–613.
15.
Wang, Xuemei, Feng Xu, Qingge Xu, et al.. (2006). Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorganic & Medicinal Chemistry Letters. 16(10). 2800–2803.
16.
Kumar, Sanjeev, et al.. (2000). Diphenhydramine Disposition in the Sheep Maternal-Placental-Fetal Unit: Gestational Age, Plasma Drug Protein Binding, and Umbilical Blood Flow Effects on Clearance. Drug Metabolism and Disposition. 28(3). 279–285.
17.
Ito, Shinya, Robert M. Gow, Zul Verjee, et al.. (1998). Intravenous and Oral Propafenone for Treatment of Tachycardia in Infants and Children: Pharmacokinetics and Clinical Response. The Journal of Clinical Pharmacology. 38(6). 496–501.
18.
Kumar, Sanjeev, George Tonn, Eddie Kwan, et al.. (1997). Estimation of Transplacental and Nonplacental Diphenhydramine Clearances in the Fetal Lamb: The Impact of Fetal First-Pass Hepatic Drug Uptake. Journal of Pharmacology and Experimental Therapeutics. 282(2). 617–632.
19.
Tonn, George, Eddie Kwan, C Hall, et al.. (1996). Hepatic first-pass uptake of diphenhydramine. A comparative study between fetal and adult sheep.. Drug Metabolism and Disposition. 24(3). 273–281.
20.
Tonn, George, et al.. (1995). Simultaneous analysis of diphenylmethoxyacetic acid, a metabolite of diphenhydramine, and its deuterium-labeled stable isotope analog in ovine plasma and urine. Journal of Chromatography B Biomedical Sciences and Applications. 663(1). 67–81.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Kenneth J. Ruterbories Breakdown of academic impact, for papers by Hiroshi Komura Breakdown of academic impact, for papers by William R. Brian Breakdown of academic impact, for papers by Sharon L. Ripp Breakdown of academic impact, for papers by Rao N. V. S. Mamidi Breakdown of academic impact, for papers by Satoru Asahi Breakdown of academic impact, for papers by Michael Schrag Breakdown of academic impact, for papers by Praveen M. Bahadduri Breakdown of academic impact, for papers by Jairam Palamanda Breakdown of academic impact, for papers by Paul Rowland